Tag Archives: ATRA

Top 10 Stocks For 2019

Overall, stocks did well on Monday, and the Dow climbed 90 points even as other major benchmarks posted similar or slightly larger percentage gains. Market participants seemed to be heartened by President Trump’s performance on the first overseas visit of his administration over the weekend, and most investors were content to wait for clearer gauges of whether the U.S. economy is still as healthy as it has been in recent years.

Yet some stocks didn’t participate in the rally, instead contending with negative news of their own. Zoe’s Kitchen (NYSE:ZOES), GOL Lineas Aereas Inteligentes (NYSE:GOL), and Sarepta Therapeutics (NASDAQ:SRPT) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Image source: Zoe’s Kitchen.

Zoe’s gets a bad review

Shares of Zoe’s Kitchen fell more than 8% after getting a downgrade. Analysts at Baird cut their rating on the restaurant-chain stock from outperform to neutral, and they reduced their price target by 20% to $20 per share. The analysts pointed out that Zoe’s is likely to have to deal with higher ingredient costs for its menu items, and that could put pressure on the company’s earnings when Zoe’s reports its first-quarter results later this week. Tough conditions in the restaurant industry have already weighed on the company, and Zoe’s shares are at their worst levels in its short history as a public company. Without a quick turnaround, it could be difficult for Zoe’s Kitchen to regain investors’ confidence going forward.

Top 10 Stocks For 2019: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Danny Vena, George Budwell, and Daniel Miller]

    With that in mind, we asked three Motley Fool contributors to identify growth stocks with intriguing potential that might not be on the radar of most investors. They pickedShopify Inc. (NYSE:SHOP), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), and Criteo S.A. (NASDAQ:CRTO).

  • [By Joseph Griffin]

    Atara Biotherapeutics (NASDAQ:ATRA) had its price target decreased by Citigroup from $25.00 to $23.00 in a report released on Monday. Citigroup currently has a sell rating on the biotechnology company’s stock.

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

  • [By Joseph Griffin]

    Atara Biotherapeutics (NASDAQ:ATRA) Director Matthew K. Fust sold 12,286 shares of Atara Biotherapeutics stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $43.57, for a total value of $535,301.02. Following the completion of the transaction, the director now directly owns 19,820 shares of the company’s stock, valued at approximately $863,557.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

  • [By George Budwell]

    With this theme in mind, I think investors shouldn’t shy away from buying shares of either Atara Biotherapeutics (NASDAQ:ATRA) or CRISPR Therapeutics (NASDAQ:CRSP)right now — even though both of these biotech stocks are currently trading close to their all-time highs. Here’s why.

  • [By Jason Hall, George Budwell, and Chuck Saletta]

    In order to help you get started, we asked three real-world investors who also write for The Motley Fool to put forth their best “buy now” growth stock ideas, and they came up with high-growth home builderLGI Homes Inc(NASDAQ:LGIH),return-to-growth restaurant chainChipotle Mexican Grill, Inc.(NYSE:CMG), and upstart immunotherapy developerAtara BioTherapeutics Inc(NASDAQ:ATRA).

Top 10 Stocks For 2019: Orchid Island Capital, Inc.(ORC)

Advisors’ Opinion:

  • [By Paul Ausick]

    Orchid Island Capital Inc. (NYSE: ORC) fell about 9.7% to post a new 52-week low of $7.85 Thursday after closing at $8.69 on Wednesday. The 52-week high is $12.60. Volume of about 5.2 million was nearly 5 times the daily average of around 1.1 million. The company lowered its monthly dividend by 3 cents last night.

Top 10 Stocks For 2019: Qualstar Corporation(QBAK)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Media headlines about Qualstar (NASDAQ:QBAK) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Qualstar earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news headlines about the electronics maker an impact score of 45.8526636437463 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Top 10 Stocks For 2019: Xenia Hotels & Resorts, Inc.(XHR)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Xenia Hotels & Resorts (NYSE:XHR) – Jefferies Group issued their Q2 2018 earnings per share (EPS) estimates for Xenia Hotels & Resorts in a note issued to investors on Thursday, May 31st. Jefferies Group analyst D. Katz forecasts that the real estate investment trust will post earnings per share of $0.62 for the quarter. Jefferies Group has a “Buy” rating and a $29.00 price objective on the stock. Jefferies Group also issued estimates for Xenia Hotels & Resorts’ Q3 2018 earnings at $0.48 EPS, Q4 2018 earnings at $0.46 EPS and FY2018 earnings at $2.06 EPS.

  • [By Shane Hupp]

    LSV Asset Management lifted its stake in Xenia Hotels & Resorts (NYSE:XHR) by 18.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,446,848 shares of the real estate investment trust’s stock after acquiring an additional 679,100 shares during the quarter. LSV Asset Management owned approximately 4.16% of Xenia Hotels & Resorts worth $87,691,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Xenia Hotels & Resorts (XHR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Stocks For 2019: Merit Medical Systems Inc.(MMSI)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Merit Medical Systems (MMSI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Merit Medical Systems, Inc. (NASDAQ:MMSI) has been assigned a consensus recommendation of “Buy” from the fourteen brokerages that are presently covering the company, Marketbeat.com reports. Thirteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $52.00.

  • [By Max Byerly]

    Eagle Boston Investment Management Inc. increased its stake in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 5.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 412,344 shares of the medical instruments supplier’s stock after buying an additional 20,334 shares during the quarter. Merit Medical Systems comprises approximately 1.9% of Eagle Boston Investment Management Inc.’s holdings, making the stock its 4th largest position. Eagle Boston Investment Management Inc. owned 0.82% of Merit Medical Systems worth $18,699,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Merit Medical Systems (MMSI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

      

    Clearside Biomedical, Inc. (NASDAQ: CLSD) shares declined 32.19 percent to close at $9.86 on Thursday. Clearside Biomedical disclosed that its Phase 2 trial of CLS-TA met primary and secondary endpoints met in 6-month trial.
    scPharmaceuticals Inc. (NASDAQ: SCPH) shares dipped 30.1 percent to close at $9.94 on Thursday after the FDA identified deficiencies in the company’s New Drug Application for FUROSCIX. However, the FDA letter did not specify deficiencies identified and notification does not reflect final decision on information under review.
    Euroseas Ltd. (NASDAQ: ESEA) fell 24.08 percent to close at $1.86. Euroseas announced completion of the spin-off of its drybulk fleet into EuroDry Ltd.
    Golar LNG Limited (NASDAQ: GLNG) fell 25.09 percent to close at $25.98 following Q1 results.
    Oragenics, Inc. (NASDAQ: OGEN) shares dropped 25 percent to close at $1.50 on Thursday.
    Guess', Inc. (NYSE: GES) dropped 19.44 percent to close at $19.60 following Q1 results.
    Cantel Medical Corp. (NYSE: CMD) dropped 15.94 percent to close at $109.09 on Thursday following FQ3 results.
    Fusion Connect, Inc. (NASDAQ: FSNN) shares fell 15.55 percent to close at $3.91.
    Build-A-Bear Workshop, Inc. (NYSE: BBW) dropped 14.44 percent to close at $8.00 after reporting Q1 results.
    Dollar Tree, Inc. (NASDAQ: DLTR) shares declined 14.28 percent to close at $82.59 after the company reported weaker-than-expected earnings for its first quarter and lowered its FY2018 earnings guidance.
    Titan Machinery Inc. (NASDAQ: TITN) dropped 13.94 percent to close at $18.09 after reporting Q1 results.
    Co-Diagnostics, Inc. (NASDAQ: CODX) declined 13.17 percent to close at $2.90 after declining 5.65 percent on Wednesday.
    Concordia International Corp. (NASDAQ: CXRX) fell 12.89 percent to close at $0.2440 after the company announced that it would be delisted from the Nasdaq.
    Sears Holdings Corporation (NASDAQ: SHLD) slipped 12.46 percent

Top 10 Stocks For 2019: Amtech Systems Inc.(ASYS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    The Trade Desk, Inc. (NASDAQ: TTD) jumped 36.2 percent to $71.82 after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance.
    WideOpenWest, Inc. (NYSE: WOW) jumped 30.4 percent to $8.80 after the company reported Q1 results.
    MoSys, Inc. (NASDAQ: MOSY) shares surged 28.6 percent to $1.9541 after the company reported better-than-expected Q1 results and issued strong Q2 forecast.
    Boxlight Corporation (NASDAQ: BOXL) gained 24 percent to $6.39.
    Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares gained 19.1 percent to $24.60. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee, which met to discuss the safety and efficacy of subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome, voted 12-8 to support its approval.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 17 percent to $10.31 after reporting Q3 results.
    ArcBest Corporation (NASDAQ: ARCB) gained 16.8 percent to $43.1457 after reporting upbeat quarterly earnings.
    Amtech Systems, Inc. (NASDAQ: ASYS) rose 16.2 percent to $8.60. Amtech posted Q2 earnings of $0.19 per share on sales of $32.783 million.
    Identiv, Inc (NASDAQ: INVE) surged 14.4 percent to $3.8450 following Q1 results.
    Omeros Corporation (NASDAQ: OMER) shares rose 14.3 percent to $18.43 following Q1 results.
    VivoPower International PLC (NASDAQ: VVPR) gained 11.5 percent to $2.71.
    Intersections Inc. (NASDAQ: INTX) gained 11.4 percent to $2.55 after reporting Q1 results.
    Noodles & Company (NASDAQ: NDLS) shares rose 10.9 percent to $8.65 following Q1 results.
    Voyager Therapeutics, Inc. (NASDAQ: VYGR) climbed 10.6 percent to $18.54 following Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) rose 10.4 percent to $5.739.
    Immersion Corporation (NASDAQ: IMMR) gained 9.6 percent to $12.69
  • [By Lisa Levin] Gainers
    Sigma Labs, Inc. (NASDAQ: SGLB) shares rose 90.9 percent to $2.52. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing.
    Oragenics, Inc. (NYSE: OGEN) shares surged 58.4 percent to $1.9005 after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study.
    Dick's Sporting Goods, Inc. (NYSE: DKS) shares climbed 23.2 percent to $37.5370 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook.
    Summer Infant, Inc. (NASDAQ: SUMR) rose 21.9 percent to $1.17 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital.
    TapImmune, Inc. (NASDAQ: TPIV) jumped 18.8 percent to $4.87. WBB Securities upgraded TapImmune from Speculative Buy to Buy.
    Movado Group, Inc. (NYSE: MOV) gained 17.2 percent to $49.45 after the company reported better-than-expected Q1 results and raised its guidance.
    ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) jumped 16.2 percent to $7.96. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating.
    Legacy Reserves LP (NASDAQ: LGCY) rose 15.5 percent to $5.6011.
    InspireMD, Inc. (NYSE: NSPR) gained 13.3 percent to $1.36 following PR announcing sustained benefit of CGuard EPS.
    Immutep Limited (NASDAQ: IMMP) shares climbed 13.2 percent to $2.7724 after the company reported new data from its ongoing TACTI-mel Phase I trial, which evaluated the combination of eftilagimod alpha, its lead compound, with Merck & Co., Inc. (NYSE: MRK)'s Keytruda in unresectable or metastatic melanoma patients, who have had a suboptimal response or had disease progression with keytruda monotherapy..
    SpartanNash Co (NASDAQ: SPTN) rose 12.2 percent to $21.20 after the company reported upbeat earnings for its first quarter on Tuesday.
    Amtech Systems, Inc. (NASDAQ: ASYS) rose 12.1 percent to
  • [By Lisa Levin] Gainers
    Oragenics, Inc. (NYSE: OGEN) shares surged 66.67 percent to close at $2.00 on Wednesday after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study.
    Sigma Labs, Inc. (NASDAQ: SGLB) shares jumped 49.24 percent to close at $1.97 on Wednesday. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing.
    ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) rose 34.45 percent to close at $9.21. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating.
    Dick's Sporting Goods, Inc. (NYSE: DKS) shares rose 25.82 percent to close at $38.35 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook.
    TapImmune, Inc. (NASDAQ: TPIV) rose 24.15 percent to close at $5.09. WBB Securities upgraded TapImmune from Speculative Buy to Buy.
    Legacy Reserves LP (NASDAQ: LGCY) jumped 23.3 percent to close at $5.98 on Wednesday.
    Summer Infant, Inc. (NASDAQ: SUMR) gained 22.92 percent to close at $1.18 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital.
    Cloud Peak Energy Inc. (NYSE: CLD) rose 21.95 percent to close at $4.00.
    SpartanNash Co (NASDAQ: SPTN) gained 21.4 percent to close at $22.92 after the company reported upbeat earnings for its first quarter on Tuesday.
    Motus GI Holdings, Inc. (NASDAQ: MOTS) rose 17.14 percent to close at $5.40.
    Movado Group, Inc. (NYSE: MOV) gained 16.59 percent to close at $49.20 after the company reported better-than-expected Q1 results and raised its guidance.
    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) climbed 15.61 percent to close at $8.22. Oramed Pharma disclosed that its patent has been allowed in the US for oral administration of proteins.
    Dorian LPG Ltd. (NYSE: LPG) rose 14.89 percent to close at $8.41. Dorian LPG confirmed receipt of unsolicited proposal fr
  • [By Stephan Byrd]

    ValuEngine cut shares of Amtech Systems (NASDAQ:ASYS) from a hold rating to a sell rating in a research note published on Wednesday morning.

    Separately, Zacks Investment Research raised Amtech Systems from a sell rating to a hold rating in a research report on Monday, April 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $14.88.

  • [By Stephan Byrd]

    Brooks Automation (NASDAQ: BRKS) and Amtech Systems (NASDAQ:ASYS) are both computer and technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Top 10 Stocks For 2019: Royal Gold Inc.(RGLD)

Advisors’ Opinion:

  • [By Reuben Gregg Brewer]

    Although gold streaming is something of a niche in the precious metals market, the largest competitors have been in the business since the 1980s,while new entrants are showing up as well (including hedge funds, private equity, and pension funds). Most investors, however, should probably stick with the largest, easiest to trade, and longest-tenured companies for now. Here are the top five.

    Company Market Cap Dividend Yield

    Franco-Nevada (NYSE:FNV) $13 billion 1.3%
    Wheaton Precious Metals (NYSE:WPM) $9 billion 1.7%
    Royal Gold (NASDAQ:RGLD) $6 billion 1.2%
    Osisko Gold Royalties Ltd. $1.6 billion 1.6%
    Sandstorm Gold Ltd. $800 million N/A

    Franco-Nevada

    The largest streaming company by market cap is Franco-Nevada. As noted above, it has investments in nearly 300 mines, 50 of which are producing. However, it has taken diversification further than its peers by investing in around 80 oil and natural gas assets (57 producing), following the same basic business model. It’s not as pure a play on metals, but if you are looking for diversification, that non-precious-metals exposure is an interesting addition to the mix. That said, gold provides roughly 70% of its revenue, with silver at 15%, and oil and gas at just 7% (the rest is, effectively, “other”), meaning that gold is still the big driver of performance here. The company has increased its dividend annually for 10 consecutive years.

  • [By Reuben Gregg Brewer]

    This, however, is where streaming company Wheaton Precious Metals (NYSE:WPM)and its peers Royal Gold (NASDAQ:RGLD) and Franco-Nevada (NYSE:FNV)come into play. Streaming companies provide cash up front to miners for the right to buy gold and silver in the future at reduced rates. Often miners use the money to build new mines. Wheaton provided $625 million in cash to Barrick for the development of Pascua-Lama. That is just one of 10 development projects in which Wheaton has invested. Its portfolio also contains 17 operating mines.

  • [By Maxx Chatsko]

    That’s not exactly great historical company. That also explains why gold fever is spreading among investors again, as it inevitably does when economic conversations turn gloomy. I think it’s better to buy and hold stocks for the long haul, but for those considering buying gold directly, I’d encourage a different strategy. That is, buying the best gold stock instead: streaming company Royal Gold (NASDAQ:RGLD).

  • [By Reuben Gregg Brewer]

    Precious metals streaming and royalty company Royal Gold, Inc. (NASDAQ:RGLD) used the commodity downturn to materially increase its production of gold and silver. The increased production, coupled with improving gold prices, led to a massive 56% increase in cash flow between fiscal 2016 and 2017. But higher gold prices have changed the opportunity set and led Royal Gold to focus on preparing for a new growth phase.

  • [By Reuben Gregg Brewer]

    Gold streaming company Franco-Nevada Corporation (NYSE:FNV) offers investors a unique way to gain exposure to precious metals, but when you compare it to peers Royal Gold, Inc. (NASDAQ:RGLD) and Wheaton Precious Metals Corp. (NYSE:WPM)it looks relatively expensive. That said, if you are looking to gold for diversification you might still find that Franco-Nevada Corporation stock is a buy.

  • [By Joseph Griffin]

    Royal Gold, Inc (NASDAQ:RGLD) (TSE:RGL) announced a quarterly dividend on Wednesday, May 30th, RTT News reports. Investors of record on Friday, July 6th will be paid a dividend of 0.25 per share by the basic materials company on Friday, July 20th. This represents a $1.00 annualized dividend and a yield of 1.11%.

Top 10 Stocks For 2019: Devon Energy Corporation(DVN)

Advisors’ Opinion:

  • [By ]

    As things stand right now, analysts anticipate that at least some Iranian oil will come off the market as a result of the sanctions. That lost output would further tighten an oil market that suddenly has little margin for error thanks to red-hot demand and tame supply growth. That’s the recipe for higher oil prices and could make top-tier U.S. oil stocks Anadarko Petroleum (NYSE:APC), Devon Energy (NYSE:DVN), and ConocoPhillips (NYSE:COP) big winners in the coming years.

  • [By Matthew DiLallo]

    As expected, EOG Resources’ U.S. oil output came in above the midpoint of its forecast and was up 15% year over year. Fueling that high-end result were the many wells EOG completed across its vast shale portfolio. The company completed 70 wells in the Delaware Basin during the quarter, with several producing more than 2,000 barrels of oil equivalent per day (BOE/D) in their first month. While the company didn’t match Devon Energy’s (NYSE:DVN) record-smashing 24,000 BOE/D two-well gusher, its wells were highly productive and generated excellent returns.

  • [By Matthew DiLallo]

    As things stand right now, analysts anticipate that at least some Iranian oil will come off the market as a result of the sanctions. That lost output would further tighten an oil market that suddenly has little margin for error thanks to red-hot demand and tame supply growth. That’s the recipe for higher oil prices and could make top-tier U.S. oil stocks Anadarko Petroleum (NYSE:APC), Devon Energy (NYSE:DVN), and ConocoPhillips (NYSE:COP) big winners in the coming years.

  • [By Stephan Byrd]

    These are some of the news headlines that may have impacted Accern Sentiment’s rankings:

    Get Devon Energy alerts:

    Devon Energy (DVN) Presents At UBS Global Oil and Gas Conference – Slideshow (seekingalpha.com) Devon Energy (DVN) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com) Top 5 Upstream Revenues: Higher Realized Prices Drive Growth (finance.yahoo.com) Comparing Stocks: COP, OXY, DVN, EOG, and APC (finance.yahoo.com) Free Research Report as Devon Energys Quarterly Revenues Advanced 7.29% (finance.yahoo.com)

    NYSE:DVN traded down $1.11 during trading hours on Friday, hitting $40.58. The company had a trading volume of 6,948,699 shares, compared to its average volume of 7,939,727. The stock has a market cap of $21.24 billion, a P/E ratio of 64.41, a price-to-earnings-growth ratio of 4.37 and a beta of 2.16. Devon Energy has a 52 week low of $28.79 and a 52 week high of $45.16. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.70.

Top 10 Stocks For 2019: Illinois Tool Works Inc.(ITW)

Advisors’ Opinion:

  • [By Shane Hupp]

    Clinton Group Inc. boosted its position in shares of Illinois Tool Works Inc. (NYSE:ITW) by 923.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 27,009 shares of the industrial products company’s stock after purchasing an additional 24,370 shares during the quarter. Clinton Group Inc.’s holdings in Illinois Tool Works were worth $3,742,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Peapack Gladstone Financial Corp reduced its stake in Illinois Tool Works (NYSE:ITW) by 7.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 19,575 shares of the industrial products company’s stock after selling 1,536 shares during the quarter. Peapack Gladstone Financial Corp’s holdings in Illinois Tool Works were worth $3,067,000 at the end of the most recent reporting period.

  • [By ]

    Cramer and the AAP team are trimming Illinois Tool Works (ITW) and Danaher (DHR) . Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

Top 10 Stocks For 2019: SandRidge Mississippian Trust II(SDR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Matador Resources (NYSE: MTDR) and SandRidge Mississippian Trust II (NYSE:SDR) are both oils/energy companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Atara Biotherapeutics: What Q1 2018 Earnings Foretell?

The big money is not in the buying and selling. But in the waiting. – Charlie Munger

Atara Biotherapeutics (NASDAQ:ATRA) is one of the most promising growers that weve encountered thus far. As follows, the company is hitting its growth inflection with a key late-stage T-cell immunotherapeutic (tab-cel, formerly known as ATA-129). In anticipating the strong data reporting, the company is preparing for launch in the EU by hiring more professionals and investing in logistics. That aside, this robust grower is deepening its research and development (R&D) into the highly lucrative, next-generation cancer treatment, chimeric antigen receptor and T-cell receptor (CAR-TCR or CAR-T). But thats not all. There is an extremely intriguing molecule in-development (ATA-188) that can shock the medical as well as investment community: it is likely the silver bullet for the highly difficult-to-manage autoimmune condition, multiple sclerosis. As reflective of the increasing intrinsic value, the stock has been on an uptrend for the past 52 weeks. Since our recommendation, the shares appreciated by $28.42 to trade at $42.75 for over 205% profits. In this research, well elucidate the latest earnings developments and catalysts that can catapult the shares to a new high.

Figure 1: Atara Biotherapeutics stock chart. (Source: StockCharts).

Fundamental Analysis

We wish to provide a brief background on Atara for new investors. Headquartered in South San Francisco, California, the company is focusing on the innovation allogenic T-cell immunotherapies (A-TCI) to service a vast number of cancers and autoimmune diseases (as depicted in figure 2). A-TCI functions quite similar to CAR-T: both therapeutics enlighten the key regulatory cells of the immune system (i.e., the T-cells which are analogous to the generals of an army). We noted in the prior research,

Ataras A-TCIs are differentiated from those of Kite Pharma (NASDAQ:KITE), a bioscience acquired by Gilead Sciences (NASDAQ:GILD). In specific, Ataras A-TCI primed the intelligence of CD8 (killer) T-cells to detect and destroy cancers. This is important, as killer T-cells are adept at attacking viruses (to kill virus-induced tumors). Of note, tab-cel is an off-the-shelf Epstein-Barr virus (EBV)-specific A-TCI. Accordingly, the FDA gave the firm the nod to initiate their two phase 3 trials (MATCH/ALLELE) for ATA-129 in patients with rituximab-refractory EBV associated PTLD. Moreover, the said molecule gained the orphan designation from both the FDA and the EMA. Furthermore, the agency designated the mentioned drug as a Breakthrough Therapy while the EMA put it in the Priority Medicines regulatory pathway. In addition, Health Canada placed it in the expedited approval category.

Figure 2: Therapeutic pipeline (Source: Atara).

Of the various developing events, we are most interested in the development regarding tab-cel. Interestingly, the clinical sites for the two phase 3 (MATCH and ALLELE) have opened in the US. And, sites elsewhere are expected to be available soon. In anticipation of the launch of tab-cel, the company pushed various programs. For instance, the hiring of Manuela Maronati signifies the anticipation of an EU approval (and for tab-cel to be initially commercialized in Europe). In addition, the recent partnership with TrakCel is certainly foretelling an upcoming launch. As the industry-leading software provider, TrakCel developed the logistics program coined Atara MatchMe. This is to improve the customer experience (to push for the most aggressive/prompt delivery of tab-cel to patients). Its important for investors to realize that a drug approval does not guarantee a launch success. Instead, prior preparations such as the hiring of experts and logistics planning (as what Atara accomplished) are crucial steps for the improved launch outcomes. Commenting on such developments, the President and CEO (Dr. Isaac Ciechanover) enthused,

During Q1 2018, we continued to advance our T-cell immunotherapy pipeline and platform. Our two phase 3 pivotal studies of tab-cel are progressing, and we remain focused on building Ataras global commercial and operational capabilities in anticipation of the first tab-cel Phase 3 results and submission of an EU conditional marketing authorization application in H1 2019. We are also excited to have recently expanded our collaboration with Memorial Sloan Kettering Cancer Center to develop next-generation CAR-T technologies, marking our entry into genetically engineered T-cells and furthering our leadership position in off-the-shelf, A-TCI. I am pleased with our strong operational and strategic execution in Q1 and look forward to both continuing this momentum and updating you on our progress throughout the rest of the year.

Aside from the upcoming tab-cel launch, were highly excited about the recent MSK-partnership to deepen the research and development (R&D) for tapping into the highly lucrative field (CAR-T) that we discussed in the prior research. Along with this catalyst, the company inked an extensive partnership with MSKs think-tank, Dr. Michel Sadelain. This contract secured the top-notch intelligence for the innovation of a novel CAR-T construct that is both gene-edited and off-the-shelf. We elucidated,

On May 08, 2018, Atara announced the expansion of its collaboration with MSK for the innovation of the next-generation CAR-T. As alluded, Ataras A-TCI functions quite similar to that of CAR-T. What is unique is that A-TCI – and CAR-T – are off-the-shelf: this confers the rapid commercialization as well offers patients convenience. As a ramification, the agreement extended the original collaboration between Atara and MSK – in the hopes to deliver stellar medicines that have the potential to transform the lives of patients afflicted by life-threatening malignancies. Pertaining to the deal specificity, Atara will have access to MSKs key biotechnologies (including a novel CAR-T construct). The said technology would enable Atara to design physiologic T-cell activation properties.

For Q1 2018 (ended on March 31), Atara reported $41.4M ($1.05 per share) in net losses compared to $28.5M ($0.88 per share) decline for the same period a year prior. The higher losses were due to the increasing R&D, which is prudent for a company advancing its therapeutic development. Investors should be cognizant that it is the norm for a relatively young bioscience like Atara to incur significant losses for many years prior to banking a net profit (due to the lengthy and low success rate of the innovation process). Nonetheless, it only takes one blockbuster to make your investment worthwhile. Regarding the balance sheet, there was $407.3M, thereby representing the 39% improvement versus the $293.3M for Q1. Based on these metrics, there should be adequate cash to fund operations into mid-2020 (prior to any additional financing).

Final Remarks

Atara is brewing two stellar analogous platforms (A-TCI and CAR-T). There are numerous catalysts powering this superb grower. One, the advancement of tab-cell development and the corporate preparation for the EU launch are signaling that the company is at its growth inflection: this is a point in the companys growth cycle where the stock can trade aggressively higher. The deepened relationship with MSK for the novel CAR-T development – to service cancer, autoimmune as well as infectious diseases – added significant value to the pipeline. Additionally, the increased cash position via the public offering to gear up for launch and to expand its R&D is highly strategic. Despite the highly favorable chances of positive outcomes for MATCH and ALLELE, there is roughly a small chance of a negative clinical binary. In that case, its most likely that the shares will depreciate over 80%, and vice versa.

Authors Notes: Were honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (IBI) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 320%, 160%, 242%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, in which we published in advance and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I like to inform our readers of Seeking Alpha’s recent policy change, in which the company implemented the paywall (not only to my articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.

Top 10 Undervalued Stocks To Own Right Now

If youre trying to edge the overall stock market, you can take your chances by picking individual issues, or you could buy an actively managed mutual fund. But some exchange-traded funds may get the job done, too, and it wont cost you much to give them a shot.

Quiz: Test Your Knowledge of ETFs

ETFs are like mutual funds, but they trade like stocks. The biggest and cheapest ETFs mirror major benchmarks, such as Standard & Poors 500-stock index. Annual fees for many ETFs are extraordinarily lowas little as 3 cents per year for every $100 invested.

Yet you dont need to pay much more for ETFs that aim to beat the major bogeys. Such ETFs hold baskets of stocks that often look very different from the S&P 500. Some of these funds focus on shares of undervalued small companies. Others tilt toward stocks with upward share-price momentum, or companies with high-quality balance sheets. You can also buy low volatility ETFs that should hold up relatively well in a market downturn.

Top 10 Undervalued Stocks To Own Right Now: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Atara Biotherapeutics (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,800 shares of the business’s stock in a transaction that occurred on Thursday, May 10th. The stock was sold at an average price of $39.85, for a total transaction of $350,680.00. Following the sale, the chief executive officer now owns 812,613 shares of the company’s stock, valued at $32,382,628.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

  • [By Max Byerly]

    Atara Biotherapeutics (NASDAQ:ATRA) SVP Derrell Porter sold 1,544 shares of the firm’s stock in a transaction on Tuesday, May 8th. The shares were sold at an average price of $40.15, for a total value of $61,991.60. Following the completion of the sale, the senior vice president now owns 12,500 shares in the company, valued at $501,875. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

  • [By Joseph Griffin]

    Atara Biotherapeutics (NASDAQ:ATRA) Director Matthew K. Fust sold 12,286 shares of Atara Biotherapeutics stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $43.57, for a total value of $535,301.02. Following the completion of the transaction, the director now directly owns 19,820 shares of the company’s stock, valued at approximately $863,557.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

  • [By Danny Vena, George Budwell, and Daniel Miller]

    With that in mind, we asked three Motley Fool contributors to identify growth stocks with intriguing potential that might not be on the radar of most investors. They pickedShopify Inc. (NYSE:SHOP), Atara Biotherapeutics, Inc. (NASDAQ:ATRA), and Criteo S.A. (NASDAQ:CRTO).

  • [By Ethan Ryder]

    Atara Biotherapeutics (NASDAQ:ATRA) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.13), MarketWatch Earnings reports.

Top 10 Undervalued Stocks To Own Right Now: First Financial Corporation Indiana(THFF)

Advisors’ Opinion:

  • [By Stephan Byrd]

    First Financial Co. Indiana (NASDAQ:THFF) declared a semiannual dividend on Thursday, May 17th, Wall Street Journal reports. Investors of record on Friday, June 15th will be given a dividend of 0.51 per share by the bank on Monday, July 2nd. This represents a dividend yield of 2.33%. The ex-dividend date of this dividend is Thursday, June 14th.

Top 10 Undervalued Stocks To Own Right Now: NF Energy Saving Corporation(NFEC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million.
    Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results.
    Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27.
    Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating.
    PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat.
    NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399.
    Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643.
    Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16.
    Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results.
    GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results.
    The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st

Top 10 Undervalued Stocks To Own Right Now: Territorial Bancorp Inc.(TBNK)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Shares of Territorial Bancorp (NASDAQ:TBNK) have been given an average rating of “Hold” by the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $33.50.

Top 10 Undervalued Stocks To Own Right Now: Freeport-McMoran, Inc.(FCX)

Advisors’ Opinion:

  • [By Todd Campbell]

    If these reasons have you interested in adding gold mining stocks to your portfolio, a few top companies to consider are Barrick Gold (NYSE:ABX), Randgold Resources (NASDAQ:GOLD), Newmont Mining (NYSE:NEM), Freeport McMoran (NYSE:FCX) and Goldcorp (NYSE:GG). All five could benefit if gold prices rally, so let’s learn more about them.

  • [By ]

    “But on days like today you have to look. You have to say that Caterpillar may not have been as articulate as it would have liked and that perhaps they should have explained that they haven’t seen peak revenues, which is how I read it. I think 3M was just trying to temper expectations so they could beat them. Freeport’s (FCX) a political mess.”

  • [By Dan Caplinger]

    Wall Street suffered a big drop on Tuesday, with the Dowdown as much as 600 points during the session before rebounding somewhat. The bond market continued to be a source of consternation for many investors, with rates rising through the 3% level for the 10-year Treasury, marking an important psychological milestone in what some predict could be a multiyear bear market for bonds. Earnings reports also brought downward pressure on certain companies, despite what was overall been a generally favorable season thus far. Polaris Industries (NYSE:PII), Freeport-McMoRan (NYSE:FCX), and Waters (NYSE:WAT) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Friday was Freeport McMoran Inc. (NYSE: FCX) which traded down over 7% at $17.97. The stocks 52-week range is $11.05 to $20.25. Volume was over 24 million compared to the daily average volume of 18 million.

  • [By ]

    Major turning points like the one were seeing right now can generate spectacular comeback moves. In fact, were already witnessing several of these rallies in our commodity-centric plays. Just look at copper miner Freeport-McMoRan Inc. (NYSE: FCX).

  • [By Matthew DiLallo]

    Shares of Freeport-McMoRan Inc.(NYSE:FCX) tumbled on Tuesday, falling nearly 16% by 3 p.m. EDTafter the company reported first-quarter results and an update on its Grasberg mine in Indonesia.

Top 10 Undervalued Stocks To Own Right Now: Textainer Group Holdings Limited(TGH)

Advisors’ Opinion:

  • [By Shane Hupp]

    Textainer Group (NYSE: TGH) is one of 17 public companies in the “Equipment rental & leasing, not elsewhere classified” industry, but how does it weigh in compared to its rivals? We will compare Textainer Group to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.

  • [By Shane Hupp]

    These are some of the news stories that may have effected Accern’s scoring:

    Get Textainer Group alerts:

    Head to Head Survey: Textainer Group (TGH) vs. The Competition (americanbankingnews.com) Textainer Group (TGH) Upgraded by ValuEngine to “Buy” (americanbankingnews.com) Financial Comparison: Textainer Group (TGH) vs. The Competition (americanbankingnews.com) Aircastle (AYR) versus Textainer Group (TGH) Head-To-Head Comparison (americanbankingnews.com) Critical Comparison: Textainer Group (TGH) and Its Rivals (americanbankingnews.com)

    Shares of Textainer Group stock opened at $17.85 on Friday. The stock has a market capitalization of $1,019.18, a P/E ratio of 43.54 and a beta of 2.50. Textainer Group has a 1 year low of $9.60 and a 1 year high of $26.50. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 2.28.

  • [By Ethan Ryder]

    Textainer Group (NYSE: TGH) is one of 17 publicly-traded companies in the “Equipment rental & leasing, not elsewhere classified” industry, but how does it contrast to its rivals? We will compare Textainer Group to similar companies based on the strength of its analyst recommendations, valuation, institutional ownership, profitability, earnings, dividends and risk.

Top 10 Undervalued Stocks To Own Right Now: Digirad Corporation(DRAD)

Advisors’ Opinion:

  • [By ]

    Some of these are even smaller nano-caps, such as medical device maker Digirad (Nasdaq: DRAD), whose entire market value is just $36 million.

    There is absolutely nothing wrong with small businesses. I own shares of quite a few in my personal account. But for the most part, I use them to fill out the growth sleeve of my portfolio and don’t consider them stable income producers.

Top 10 Undervalued Stocks To Own Right Now: Sonic Corp.(SONC)

Advisors’ Opinion:

  • [By Logan Wallace]

    Sonic Drive-In (NASDAQ:SONC) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

  • [By Peter Graham]

    Small cap burger stock Sonic Corporation (NASDAQ: SONC) reported fiscal Q1 2018 earnings after the market closed Thursday that exceeded Wall Street expectations. Total revenues were $105.428 million versus $129.551 million assystem same-store sales declined 1.7% – consisting of a 1.6% same-store sales decrease at franchise drive-ins and a 3.2% decrease at company drive-in. Net income totaled $11.4 million versus net income of $13.1 million. The CEO commented:

  • [By ]

    Among McDonald’s main rivals, identified by FactSet, are Starbucks Corp. (SBUX) , down almost 5.5%; Yum! Brands (YUM) , which owns KFC, Pizza Hut and Taco Bell, up 32%; and burger chain Sonic Corp. (SONC) , down about 2%. These are all year-over-year percentages.

Top 10 Undervalued Stocks To Own Right Now: Tarena International, Inc.(TEDU)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Tarena International (NASDAQ: TEDU) and TAL Education (NYSE:TAL) are both business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Top 10 Undervalued Stocks To Own Right Now: ZIOPHARM Oncology Inc(ZIOP)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Ziopharm Oncology (ZIOP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Todd Campbell]

    It garnered a lot of attention in 2015 when Ziopharm (NASDAQ:ZIOP) announced it would use its “sleeping beauty” technology to improve upon chimeric antigen receptor T-cell therapies that it was developing. Then, its mosquitoes that are engineered so that they can’t reproduce and spread disease won investor interest during the Zika virus outbreak in 2015 and 2016.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Stellar Biotechnologies, Inc. (NASDAQ: SBOT) fell 42 percent to $2.25 in pre-market trading after dropping 31.45 percent on Thursday. Stellar Biotechnologies priced 2.075 million units at price of $2.65 per unit.
    Symantec Corporation (NASDAQ: SYMC) shares fell 25.2 percent to $21.82 in pre-market trading. Symantec reported better-than-expected earnings for its fourth quarter, but issued weak second-quarter guidance.
    AGM Group Holdings Inc. (NASDAQ: AGMH) shares fell 9.5 percent to $10 in pre-market trading after surging 7.79 percent on Thursday.
    ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) fell 8.9 percent to $4.11 in pre-market trading after the company posted wider-than-expected Q1 loss.
    Redfin Corporation (NASDAQ: RDFN) fell 8.6 percent to $21.00 in pre-market trading after reporting Q1 results.
    Geron Corporation (NASDAQ: GERN) fell 8.3 percent to $3.33 in pre-market trading. Geron posted a Q1 loss of $0.04 per share.
    Talend S.A. (NASDAQ: TLND) shares fell 6 percent to $56 in pre-market trading after reporting Q1 results.
    Flotek Industries, Inc. (NYSE: FTK) fell 5.4 percent to $3.54 in pre-market trading after dropping 2.35 percent on Thursday.
    Halozyme Therapeutics, Inc. (NASDAQ: HALO) fell 5.1 percent to $18.95 in pre-market trading after reporting Q1 results.
    Yelp Inc. (NYSE: YELP) shares fell 4.9 percent to $45.40 in pre-market trading. Yelp reported stronger-than-expected results for its first quarter on Thursday.
    Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares fell 3.3 percent to $7.50 in pre-market trading after dropping 4.32 percent on Thursday

  • [By Paul Ausick]

    Ziopharm Oncology Inc. (NASDAQ: ZIOP) dropped more than 10% Tuesday to post a 52-week low of $3.77 after closing at $4.20 on Monday. The 52-week high is $7.88. Volume was around 3.7 million, more than double the daily average. The company reported Tuesday on progress of two platforms it is developing and investors did not like what they heard.

Best Clean Energy Stocks To Own For 2018

&l;p&g;&l;img class=&q;dam-image bloomberg size-large wp-image-41903517&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/41903517/960×0.jpg?fit=scale&q; data-height=&q;1390&q; data-width=&q;960&q;&g; A rainbow arcs over wind turbines at a wind farm in Scotland. Mike Wilkinson/Bloomberg

As the amount of renewable energy in global electricity networks continues to surge, a new question arises &a;ndash; when will renewables become the dominant source of energy?

A new report, the &l;a href=&q;https://www.lr.org/techradar&q; target=&q;_blank&q;&g;Lloyd&a;rsquo;s Register 2018 Technology Radar&l;/a&g;, examines this issue and also looks at which technologies are likely to have the biggest impact in different countries and what are the key drivers and barriers to success.

A survey of 800 key industry figures found that China would be the first country to achieve grid parity, in 2022, followed by Spain and the United Arab Emirates two years later in 2024. This is the same year that Germany and the UK are expected to see grid parity for wind power, followed a year later by Denmark and the USA. The International Renewable Energy Agency (IRENA) &l;a href=&q;http://www.irena.org/newsroom/pressreleases/2018/Jan/Onshore-Wind-Power-Now-as-Affordable-as-Any-Other-Source&q; target=&q;_blank&q;&g;said recently&l;/a&g; that clean energy sources will be cheaper than fossil fuels by 2020.

Best Clean Energy Stocks To Own For 2018: Peak Resorts, Inc.(SKIS)

Advisors’ Opinion:

  • [By Monica Gerson]

    Peak Resorts Inc (NASDAQ: SKIS) is projected to report its quarterly earnings at $0.40 per share on revenue of $42.59 million.

    BMC Stock Holdings Inc (NASDAQ: STCK) is expected to post its quarterly earnings at $0.17 per share on revenue of $449.59 million.

Best Clean Energy Stocks To Own For 2018: Occidental Petroleum Corporation(OXY)

Advisors’ Opinion:

  • [By Chris Lange]

    Occidental Petroleum Corp.s (NYSE: OXY) short interest decreased to 11.44 million shares from the previous reading of 11.77 million. Shares recently traded at $69.65, in a 52-week range of $57.20 to $78.09.

  • [By Ben Levisohn]

    Stocks that made the cut include General Motors (GM), Coca-Cola Company (KO), Occidental Petroleum (OXY), JPMorgan Chase (JPM), and General Electric (GE).

  • [By Michael Flannelly]

    Early on Monday, analysts at Deutsche Bank lowered their price target on Occidental Petroleum Corporation (OXY) to reflect a lower-than-expected valuation of an asset that the oil and gas exploration company is trying to sell.

    Though the analysts lowered OXY’s price target from $114 to $109, they still maintain a “Buy” rating on the stock. The new price target suggests a 22% upside to the stock’s Friday closing price of $89.49.

    Deutsche Bank analyst Paul Sankey said, “Bloomberg Finance LP reports that Oxy is seeking sale of 40% of Mideast operations for around $8bn, which would imply $20bn total value for the unit. However reportedly some suitors are valuing the asset at around $15bn. This is a relatively negative valuation against our previous view that Oxy would be seeking $25+bn for its MENA business. We are cutting our price target to $109/share to reflect this lower implied valuation.”

    Occidental Petroleum shares were up 96 cents, or 1.07%, during pre-market trading on Monday. The stock is up 16.81% year-to-date.

  • [By Lee Jackson]

    These companies also reported insider buying last week: Carrizo Oil and Gas Inc. (NASDAQ: CRZO), Medifast Inc. (NYSE: MED), Medley Capital Corp. (NYSE: MCC), Occidental Petroleum Corp. (NYSE: OXY) and Sothebys (NYSE: BID).

Best Clean Energy Stocks To Own For 2018: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Best Clean Energy Stocks To Own For 2018: GigaMedia Limited(GIGM)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested small cap online gaming and cloud computing GigaMedia Limited (NASDAQ: GIGM) as a bullish long trade: